(Q37803154)

23 August 2017

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents (English)

1 reference

23 August 2017

1 reference

1 reference

Kathleen I. Pritchard

Kathleen I Pritchard

11

0 references

Vuk Stambolic

Vuk Stambolic

2

0 references

Bingshu E. Chen

Bingshu E Chen

4

0 references

Pamela J Goodwin

Pamela J Goodwin

1

0 references

Dawn L. Hershman

7

Dawn L Hershman

1 reference

23 August 2017

9

Jennifer A Ligibel

1 reference

23 August 2017

Julie Lemieux

3

1 reference

23 August 2017

Wendy R Parulekar

5

1 reference

23 August 2017

Karen A Gelmon

6

1 reference

23 August 2017

Timothy J Hobday

8

1 reference

23 August 2017

Ingrid A Mayer

10

1 reference

23 August 2017

Timothy J Whelan

12

1 reference

23 August 2017

Priya Rastogi

13

1 reference

23 August 2017

Lois E Shepherd

14

1 reference

23 August 2017

language of work or name

English

0 references

publication date

26 October 2010

1 reference

Breast Cancer Research and Treatment

23 August 2017

1 reference

23 August 2017

126

1 reference

23 August 2017

215-220

1 reference

23 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-010-1224-1

23 August 2017

0 references

cites work

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin and reduced risk of cancer in diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Sulphonylureas and cancer: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Long-term metformin use is associated with decreased risk of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metabolic syndrome as a prognostic factor for breast cancer recurrences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Weight loss in breast cancer patient management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

IGF and insulin receptor signaling in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Insulin-lowering effects of metformin in women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Role of AMP-activated protein kinase in mechanism of metformin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Utility of metformin in breast cancer treatment, is neoangiogenesis a risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-010-1224-1

10.1007/S10549-010-1224-1

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference